Metoclopramide --- Leukemia Stem Cells
Hi friends, just sharing the following here:
Metoclopramide inhibits proliferation of leukemia stem cells
A research team at Inselspital, Bern University Hospital and the University of Bern has identified and tested the use of an agent that can effectively inhibit the proliferation of leukemia stem cells.
Metoclopramide, used as an anti-emetic medication - commonly used to treat nausea and vomiting, interrupts the unique CD93 signaling pathway that only leukemia stem cells use to proliferate.
This opens up a therapeutic approach using Metoclopramide to selectively eliminate leukemia stem cells.
What are the next research activities?
The results have pinpointed CD93 as a specific regulator responsible for leukemia stem cell proliferation.
This identifies a promising pathway to targeting leukemia stem cells.
Further studies must now prove the clinical effect and relevance.
Prof. Adrian Ochsenbein outlines the following picture:
"Thanks to this pool of expertise, we were able to identify Metoclopramide as a promising candidate for Chronic Myeloid Leukemia (CML) therapy.
And with the broad-based research infrastructure and our excellent national and international network, we are hopefully in a position to present clinical results within a reasonable timescale.
Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells
JANUARY 26, 2021
• CD93 is a marker for leukemia stem cells (LSCs) in CML
• The intracellular domain of CD93 promotes stemness and self-renewal of CML LSCs
• The anti-emetic drug metoclopramide blocks CD93 signaling in LSCs